Vilitra (Vardenafil) is a medication commonly prescribed for erectile dysfunction (ED), functioning as a phosphodiesterase type 5 (PDE5) inhibitor to enhance blood flow to the penis. However, its use in patients with severe liver fibrosis requires careful consideration due to the liver’s crucial role in drug metabolism. Understanding the interplay between Vilitra and liver health is essential for ensuring safe and effective treatment. Liver fibrosis represents a progressive accumulation of scar tissue in the liver, usually resulting from chronic liver damage due to conditions such as hepatitis, alcohol abuse, or non-alcoholic fatty liver disease. The fibrosis ranges from mild to severe, with severe liver fibrosis potentially progressing to cirrhosis. This stage is marked by extensive liver damage and compromised liver function, which can significantly affect how medications are processed.
